Company: INGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029993
Chunk: 54

Company: Inogen Inc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 54
---

    % of Revenue

    (dollar amounts in thousands)
     
    2024

    2023

    $

    %

    2024

    2023

    Research and development expense
     
    $
    21,610

    $
    20,840

    $
    770

    3.7
    %

    6.4
    %

    6.6
    %

Research and development expense increased $0.8 million for the year ended December 31, 2024 from the year ended December 31, 2023, representing an increase of 3.7%. This was due primarily to a $2.3 million increase in amortization costs of intangible assets related to the Physio-Assist acquisition, partially offset by a $1.6 million decrease in product development costs.

 67

Sales and marketing expense 

    Years ended December 31,

    Change 2024 vs. 2023

    % of Revenue

    (dollar amounts in thousands)
     
    2024

    2023

    $

    %

    2024

    2023

    Sales and marketing expense
     
    $
    103,069

    $
    107,091

    $
    (4,022
    )

    -3.8
    %

    30.7
    %

    33.9
    %

Sales and marketing expense decreased $4.0 million for the year ended December 31, 2024 from the year ended December 31, 2023, a decrease of 3.8%. This was primarily due to decreases of $8.5 million in consulting fees, $1.9 million in dues, fees and licenses, and $1.6 million in credit card and financing fees, partially offset by an increase of $5.1 million in media and advertising costs, $1.5 million in personnel-related expenses, and $0.9 million in travel costs. In the year ended December 31, 2024, we spent $32.2 million in media and advertising costs versus $27.1 million in 2023.

General and administrative expense 

    Years ended December 31,

    Change 2024 vs. 2023

    % of Revenue

    (dollar amounts in thousands)
     
    2024

    2023

    $

    %

    202